The issue of HIV drug resistance impacts greatly on treatment regimens for HIV and AIDS patients
The issue of HIV drug resistance impacts greatly on treatment regimens for HIV and AIDS patients
(PRWEB) January 8, 2004
The issue of HIV drug resistance impacts greatly on treatment regimens for HIV and AIDS patients, therefore impacting commercially on HIV therapeutic products globally. The growth in resistance monitoring is a development that HIV pharmaceutical companies need to be aware of and initiate collaborative ventures to improve product uptake. Relevant case reports and strategic proposals are discussed.
Scope
Explanation of why HIV drug resistance emerges, how it is monitored and what its impact is from both a clinical and commercial aspect
Provides an overview of all resistance mutations for all HIV drugs on the market and these affect product lifetime and development
Detailed description of entry inhibitors and their mechanisms of action and how resistance will affect this particular class of HIV drug
Identifies specific areas on which to focus on in the field of resistance and gives strategic recommendations
Report Highlights
The issue of inconcordance of plasma and sanctuary site viral evolution is a critical one that is being overlooked in this arena. Manufacturers need to be aware of the bioavailability of their drugs at these sites, as it will affect long-term resistance, efficacy and product lifetime.
The trend towards monitoring of virus-dependant factors such as coreceptor density and alterations in envelope protein distinct from the target site is growing and needs to be monitored carefully to facilitate probability of treatment success with this particular class of HIV therapy.
Datamonitor believes that relegation of entry inhibitors to salvage therapy is a suboptimal use of this novel class of HIV therapeutic drugs.
This report is designed to:
Understand HIV drug resistance, the monitoring assays available and its impact on clinical and commercial success of a drug
Be aware of the current and potential HIV entry inhibitors in the market and the impact of drug resistance in this class
Gives strategic recommendations for companies to focus on to overcome HIV drug resistance-related issues
For a complete index of this report click on http://www.researchandmarkets.com/reports/41898
About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute thousands of major research publications from the world’s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.
For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com
###
©Copyright 1997-
, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.
Finally, an issue that I am passionate about. I have looked for information of this caliber for the last several hours. Your site is greatly appreciated.